Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Triple negative breast cancer: looking for the missing link between biology and treatments.

Oncotarget - 29 Sept 2015

Palma Giuseppe, Frasci Giuseppe, Chirico Andrea, Esposito Emanuela, Siani Claudio, Saturnino Carmela, Arra Claudio, Ciliberto Gennaro, Giordano Antonio, D'Aiuto Massimiliano

Abstract excerpt

The so called "Triple Negative Breast Cancer" (TNBC) represents approximately 15-20% of breast cancers. This acronym simply means that the tumour does not express oestrogen receptor (ER) and progesterone receptor (PR) and does not exhibit amplification of the human epidermal growth factor receptor 2 (HER2) gene. Despite this unambiguous definition, TNBCs are an heterogeneous group of tumours with just one common...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to DNA Repair

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Recurrence, Local

Share to Neovascularization, Pathologic

Share to Quality of Life

Share to Randomized Controlled Trials as Topic

Share to Receptors, Androgen

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 26387133
DOI: 10.18632/oncotarget.5306
PMCID: PMC4694936

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Triple negative breast cancer: looking for the missing link between biology and treatments.PMID 26387133Read ↗

Triple-negative breast cancer and the need for new therapeutic targets.Semantic proximity Read ↗

How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategiesSemantic proximity Read ↗

Advances in the Understanding of the Pathogenesis of Triple-Negative Breast Cancer.Semantic proximity Read ↗

Triple-negative breast cancer.Semantic proximity Read ↗

Molecular pathways and therapeutic targets linked to triple-negative breast cancer (TNBC).Semantic proximity Read ↗

Molecular targets and therapies associated with poor prognosis of triple‑negative breast cancer (Review)Semantic proximity Read ↗

Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of researchSemantic proximity Read ↗

Triple-negative breast cancer.Semantic proximity Read ↗

Triple-negative breast cancer: unique biology and its management.Semantic proximity Read ↗

New Biomarkers and Treatment Advances in Triple-Negative Breast CancerSemantic proximity Read ↗

Triple-negative breast cancer: from none to multiple therapeutic targets in two decadesSemantic proximity Read ↗

Targeting Triple‐Negative Breast Cancer: Resistance Mechanisms and Therapeutic AdvancementsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.